A new study conducted by Columbia University Mailman School of Public Health and Columbia University Irving Medical Center estimates that over 5.5 million people in the US used hallucinogens...
Cybin Inc.
Awakn Life Sciences has signed its first licensing partnership agreement in Canada with Ontario-based Wellbeings Pain Management and Dependency Clinic, which is focused on multi-disciplinary, evidence-based,...
Optimi Health has received approval from Health Canada to manufacture and distribute psychedelic medicines.
Awakn Life Sciences is expanding its commercial operations into the US through its first licensing partnership with Revitalist Lifestyle and Wellness – one of the largest...
Small Pharma has received approval for an interaction study between the company’s lead N, N-dimethyltryptamine (DMT) candidate – SPL026 – and serotonin reuptake inhibitors (SSRIs).
The 2022 International Forum on Consciousness returns with its 2022 topic “As Above, So Below”, and will feature a diverse group of thought leaders to explore...
Optimi Health has launched Blue Serenity – Canada’s first natural therapeutic psilocybin product, in collaboration with psilocybin patient advocate Thomas Hartle.
Launched by Subreddit r/HPPD in partnership with the scientific research app Quantified Citizen, the retrospective, observational study aims to investigate possible links between Hallucinogen Persisting Perception...
The Microdosing Collective has stated it is committed to a world where sub-perceptible microdosing of psychedelics is legal, accessible and safe.